Cryoneurolysis: A Novel Treatment for Management of Spasticity. Presentation of a Case Series.
Scientific Abstract
Spasticity is a motor phenomenon occurring in disorders of the central nervous system that impacts on active and passive function, and quality of life. Pharmacological, physical and surgical management options are available, each of which have limitations. Cryoneurolysis is a technique developed for the treatment of pain which involves the controlled freezing and thawing of peripheral nerves. Recent case reports and series have suggested it may offer a novel treatment approach for pain associated with spasticity.
To report on the evaluation of cryoneurolysis in the first cohort of patients treated in a UK spasticity clinic.
Eight patients with a variety of neurological conditions (aged 25-75 years) underwent cryoneurolysis. Each had been receiving regular botulinum toxin injections and had ongoing treatment goals. All patients first underwent diagnostic nerve blocks with local anaesthetic to determine their appropriateness for the treatment. Cryoneurolysis was then performed with ultrasound and nerve stimulator guidance. Assessments included goal attainment, Modified Ashworth Scale (MAS), ArmA, LegA and the patient reported impact of spasticity scale (PRISM), alongside patient satisfaction and side effect questionnaires. Assessments were at baseline and at regular intervals over 9 to 12 months.
All patients attained at least one of their goals, with sustained effect for more than 6 months. MAS demonstrated mixed or modest improvements. Functional outcome measures (ArmA/LegA) showed several meaningful improvements, particularly in passive function. There was an indication of an improvement in PRISM across domains, which plateaued at 6 months. Post-procedure pain was the most common side effect but subsided in all affected patients by 3 months. Patient satisfaction was positive.
Our findings contribute to a growing base of case reports and series suggesting that cryoneurolysis could be a potentially useful treatment modality for spasticity. Future controlled studies should aim to evaluate cost-effectiveness and compare with existing treatments.
Similar content
Paper
Early neurological deterioration in patients with minor stroke: A single-center study conducted in Vietnam.
2025. PLoS One, 20(5)e0323700.
Free Full Text at Europe PMC
PMC12088008
Paper
Memory consolidation during sleep: a facilitator of new learning?
2026. Neuropsychologia, 221:109320.
Free Full Text at Europe PMC
PMC7618826
Paper
Transcranial direct current stimulation for upper and lower limb motor function in young people with Cerebral Palsy: a randomised controlled pilot study.
2026. Disabil Rehabil, 48(13):4078-4094.
Paper
Sleep regularity index as a novel indicator of sleep disturbance in stroke survivors: a secondary data analysis.
2025. Sci Rep, 15(1):17510.
Free Full Text at Europe PMC
PMC12092764
Cryoneurolysis: A Novel Treatment for Management of Spasticity. Presentation of a Case Series.
Scientific Abstract
Spasticity is a motor phenomenon occurring in disorders of the central nervous system that impacts on active and passive function, and quality of life. Pharmacological, physical and surgical management options are available, each of which have limitations. Cryoneurolysis is a technique developed for the treatment of pain which involves the controlled freezing and thawing of peripheral nerves. Recent case reports and series have suggested it may offer a novel treatment approach for pain associated with spasticity.
To report on the evaluation of cryoneurolysis in the first cohort of patients treated in a UK spasticity clinic.
Eight patients with a variety of neurological conditions (aged 25-75 years) underwent cryoneurolysis. Each had been receiving regular botulinum toxin injections and had ongoing treatment goals. All patients first underwent diagnostic nerve blocks with local anaesthetic to determine their appropriateness for the treatment. Cryoneurolysis was then performed with ultrasound and nerve stimulator guidance. Assessments included goal attainment, Modified Ashworth Scale (MAS), ArmA, LegA and the patient reported impact of spasticity scale (PRISM), alongside patient satisfaction and side effect questionnaires. Assessments were at baseline and at regular intervals over 9 to 12 months.
All patients attained at least one of their goals, with sustained effect for more than 6 months. MAS demonstrated mixed or modest improvements. Functional outcome measures (ArmA/LegA) showed several meaningful improvements, particularly in passive function. There was an indication of an improvement in PRISM across domains, which plateaued at 6 months. Post-procedure pain was the most common side effect but subsided in all affected patients by 3 months. Patient satisfaction was positive.
Our findings contribute to a growing base of case reports and series suggesting that cryoneurolysis could be a potentially useful treatment modality for spasticity. Future controlled studies should aim to evaluate cost-effectiveness and compare with existing treatments.
Citation
2025. Adv Rehabil Sci Pract, 14:27536351251340216.
DOI
10.1177/27536351251340216
Free Full Text at Europe PMC
PMC12264415Similar content
Paper
Early neurological deterioration in patients with minor stroke: A single-center study conducted in Vietnam.
2025. PLoS One, 20(5)e0323700.
Free Full Text at Europe PMC
PMC12088008
Paper
Memory consolidation during sleep: a facilitator of new learning?
2026. Neuropsychologia, 221:109320.
Free Full Text at Europe PMC
PMC7618826
Paper
Transcranial direct current stimulation for upper and lower limb motor function in young people with Cerebral Palsy: a randomised controlled pilot study.
2026. Disabil Rehabil, 48(13):4078-4094.
Paper
Sleep regularity index as a novel indicator of sleep disturbance in stroke survivors: a secondary data analysis.
2025. Sci Rep, 15(1):17510.
Free Full Text at Europe PMC
PMC12092764